8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Feb 25, 2026·SEC
Alector, Inc.(ALEC)Earnings, Financials & Key Ratios
ALEC•NASDAQ
$2.01
Price updated Jul 2, 2026
AboutAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Show more
- Revenue$21M-79.1%
- EBITDA-$136M
- Net Income-$143M-20.1%
- EPS (Diluted)-1.39-13.0%
- Gross Margin54.09%-45.9%
- EBITDA Margin-646.93%-377.8%
- Operating Margin-692.83%-380.5%
- Net Margin-679.16%-473.7%
- ROE-181.56%-99.0%
ALEC Price & Volume
Alector, Inc. (ALEC) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pipeline Costs Threaten Alector Liquidity Position
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity depletion risk
Key Thesis Takeaways
- Alector faces a precarious financial outlook as its immuno-neurology pipeline development continues to outpace revenue generation, leading to a rapid erosion of shareholder equity from $134.2 million in 2023Q4 to $10.4 million in 2026Q1.
- The company's reliance on lumpy milestone-based revenue, which saw a 71.5% year-over-year contraction in 2026Q1, creates significant uncertainty regarding its ability to fund late-stage clinical trials.
- Investors should monitor the firm's critical cash position of $77.0 million as of 2026Q1, as the current burn rate suggests a high probability of future dilutive financing to sustain operations.
Verdict Logic
the company's rapid depletion of cash reserves to $77.0 million against significant quarterly operating losses suggests an imminent risk of shareholder dilution that outweighs current pipeline potential.
ALEC Growth Metrics
Alector, Inc. (ALEC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-0.05%
3 Years-46%
TTM-79.15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.38%
Return on Capital
10 Years-30.34%
5 Years-28.38%
3 Years-38.32%
Last Year-51.43%
ALEC Recent Earnings
Alector, Inc. (ALEC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.21+40.0%
$0.35
Rev
$1M-89.2%
$10M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.34+12.8%
$0.39
Rev
$6M+218.6%
$2M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.34+19.0%
$0.42
Rev
$3M+82.8%
$2M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.30+33.3%
$0.45
Rev
$8M+180.7%
$3M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.21vs $0.35+40.0% | $1Mvs $10M-89.2% |
| Q1 2026 | Feb 25, 2026 | $0.34vs $0.39+12.8% | $6Mvs $2M+218.6% |
| Q4 2025 | Nov 6, 2025 | $0.34vs $0.42+19.0% | $3Mvs $2M+82.8% |
| Q3 2025 | Aug 7, 2025 | $0.30vs $0.45+33.3% | $8Mvs $3M+180.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Alector, Inc. (ALEC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.01 | $223.16M | -1.45 | -79.07% | -679.16% | -181.56% | — | |
| $9.58 | $501.54M | -2.11 | -92.84% | -260.92% | -49.88% | — | |
| $25.20 | $4.31B | 11.00 | 11.87% | 34.3% | 35.65% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $2.58 | $239.09M | -4.78 | — | — | -38.76% | — | |
| $1.68 | $44.66M | -0.90 | 257.14% | — | -170.86% | — |
Compare ALEC vs Peers
Alector, Inc. (ALEC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALEC SEC Filings & Documents
Alector, Inc. (ALEC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ALEC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALEC Frequently Asked Questions
Alector, Inc. (ALEC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Alector, Inc.'s revenue?
Alector, Inc. (ALEC) reported $18.4M in revenue for fiscal year 2025. This represents a 4327% increase from $0.4M in 2016.
How fast is Alector, Inc. growing?
Alector, Inc. (ALEC) saw revenue decline by 79.1% over the past year.
Is ALEC profitable?
Alector, Inc. (ALEC) reported a net loss of $125.4M for fiscal year 2025.
Dividend & Returns
What is ALEC's return on equity?
Alector, Inc. (ALEC) has a return on equity (ROE) of -181.6%. Negative ROE indicates the company is unprofitable.
What is Alector, Inc.'s free cash flow?
Alector, Inc. (ALEC) had negative free cash flow of $173.2M in fiscal year 2025, likely due to heavy capital investments.